Skip to main content

Table 1 Baseline and follow-up characteristics of anti-MCV isotypes for responders compared to non-responders to RTX treatment, respecting baseline seropositivity, mean titers and relative titer changes upon RTX treatment

From: Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

50 RA patients upon RTX treatment RRs (n = 37) NRRs (n = 13)
  AMCV IgG
Positive at baseline (n, %) 37 100 % 13 100 %
Negative at baseline (n, %) 0 0 % 0 0 %
Mean baseline titer (v ± SD in U/ml) 769.05 891.04 856.99 982.98
Titer decrease (n, %) 31 84 % 11 85 %
Titer increase (n, %) 6 16 % 1 7.5 %
Mean titer at 24 weeks (v ± SD in U/ml) 390.46 432.06 662.67 834.47
Percentage decline/Wilcoxon P value 49.22 % P <0.0001 22.68 % P = 0.02
Mann–Whitney U P value (24 weeks) P = 0.288
Seronormalization (n, %) 4 11 % 1 8 %
Seroconversion (n, %) 0 0 % 0 0 %
  AMCV IgM
Positive at baseline (n, %) 16 43 % 9 69 %
Negative at baseline (n, %) 21 57 % 4 31 %
Mean baseline titer (v ± SD in U/ml) 39.97 94.43 106.06 147.25
Titer decrease (n, %) 33 89 % 8 62 %
Titer increase (n, %) 4 11 % 5 38 %
Mean titer at 24 weeks (v ± SD in U/ml) 10.41 10.84 39.80 48.62
Percentage decline/Wilcoxon P value 73.95 % P <0.0001 62.5 % P = 0.03
Mann–Whitney U P value (24 weeks) P = 0.0003
Seronormalization (n, %) 11 69 % 3 33 %
Seroconversion (n, %) 0 0 % 1 25 %
  AMCV IgA
Positive at baseline (n, %) 12 32 % 9 69 %
Negative at baseline (n, %) 25 68 % 4 31 %
Mean baseline titer (v ± SD in U/ml) 90.14 240.85 182.51 483.40
Titer decrease (n, %) 32 87 % 9 69 %
Titer increase (n, %) 5 13 % 4 31 %
Mean titer at 24 weeks (v ± SD in U/ml) 29.84 89.06 218.57 513.17
Percentage decline/Wilcoxon P value 67 % P <0.0001 19.76 % P = 0.17
Mann–Whitney U P value (24 weeks) P = 0.007
Seronormalization (n, %) 5 42 % 2 22 %
Seroconversion (n, %) 0 0 % 0 0 %
  1. AMCV, antibodies against mutated citrullinated vimentin; n, number of patients; NRRs, non-responders to RTX; RRs, responders to RTX; RTX, rituximab; SD, standard deviation; v, value